Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
Adopting the final Annual Report
PHI intends to convene a general meeting to adopt the annual report for the fiscal year 2023/2024 and to amend resolutions regarding election of board members and the number of board members.
BioStock: PHI’s new CEO: “I am excited to lead us forward with new energy”
Anders Månsson was recently appointed CEO of Phase Holographic Imaging. With extensive leadership experience in the international life sciences sector, he aims to expand PHI’s global reach and position the company as a leader in non-invasive cell quality control technologies. BioStock spoke with him about his vision for the future.
Bulletin from the annual general meeting of Phase Holographic Imaging PHI AB (publ)
Phase Holographic Imaging PHI AB (publ) held its annual general meeting on 31 October 2024. The following resolutions were made.
PHI secures a loan from Altium SA
Phase Holographic Imaging PHI AB (“PHI”) announces that the Company has been provided a loan of SEK 7 million from the main shareholder Altium SA. PHI and Altium SA are also in dialogues regarding long-term financing of PHI.
PHI AB’s warrant exercise registered at the Swedish Companies Registration Office
Phase Holographic Imaging PHI AB (“PHI” or “Company”) today announces that the new shares from the exercise of warrants of series TO 4 have been registered at the Swedish Companies Registration Office.
PHI appoints Anders Månsson as new CEO
The board of Phase Holographic Imaging (PHI) has today appointed Anders Månsson as the new CEO of PHI as of November 1, 2024. The current CEO, Patrik Eschricht, will remain in his role until November 1, 2024, and ensure a smooth handover to Anders Månsson.
Phase Holographic Imaging PHI AB receives approx. SEK 5.2 million through warrant exercise
On 3 October 2024, the exercise period for warrants of series TO 4, which were issued in connection with Phase Holographic Imaging PHI AB’s (“PHI” or the “Company”) rights issue of units in 2022 (“TO 4”), ended. In total, 1,129,513 warrants of series TO 4 were exercised, corresponding to a subscription rate of approximately 83.9 percent. PHI is thus provided approximately SEK 5.2 million before deduction of transaction related costs.
BioStock: PHI accelerates growth with record order
PHI recently received its most significant order from Altium, comprising 20 HoloMonitor systems and additional components. This milestone aligns with the positive growth trajectory since the start of the year. PHI is also approaching the final exercise day of their TO 4 warrants on October 3, raising up to SEK 6.2 million before issue costs. BioStock reached out to CEO Patrik Eschricht for a comment.
Notice of Annual General Meeting in Phase Holographic Imaging PHI AB (publ)
The shareholders of Phase Holographic Imaging PHI AB (publ), reg. nr. 556542-7811, are hereby invited to attend the annual general meeting on the 31 October 2024 at 11.00 at the company´s office at Skiffervägen 48 in Lund.
The last day of trading in warrants of series TO 4 is on 1 October 2024
The 1st of October 2024 is the last day of trading in warrants of series TO 4, which were issued in connection with Phase Holographic Imaging PHI AB’s preferential rights issue of units that was carried out in 2022. The exercise period runs until 3 October 2024.